JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.73, sa.4, ss.387-396, 2019 (SCI İndekslerine Giren Dergi)
BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.